Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$712.20 +1.2%	$614.60	$510.05 ▼ $716.62	$43.59B	0.41	379,007 shs	353,562 shs
ASND Ascendis Pharma A/S	$194.27 +0.2%	$180.56	$111.09 ▼ $199.99	$11.89B	0.39	548,125 shs	357,323 shs
INSM Insmed	$136.10 +0.8%	$111.35	$60.40 ▼ $136.90	$28.77B	0.96	3.07 million shs	2.19 million shs
ONC BeOne Medicines	$306.05 +2.7%	$285.26	$170.99 ▼ $330.63	$33.54B	0.21	328,635 shs	360,221 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	0.00%	+7.91%	+5.70%	+21.83%	+37.67%
ASND Ascendis Pharma A/S	0.00%	-0.02%	+11.34%	+10.58%	+40.32%
INSM Insmed	0.00%	+3.20%	+25.22%	+89.87%	+77.98%
ONC BeOne Medicines	0.00%	-2.43%	+2.35%	+24.45%	+30,604,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARGX argenex	3.6031 of 5 stars	2.5	2.0	0.0	2.7	1.7	4.4
ASND Ascendis Pharma A/S	3.3419 of 5 stars	4.5	1.0	0.0	4.2	1.7	0.6
INSM Insmed	3.7515 of 5 stars	2.5	4.0	4.3	3.0	0.8	0.6
ONC BeOne Medicines	0.6508 of 5 stars	1.5	0.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	3.09	Buy	$766.50	7.62% Upside
ASND Ascendis Pharma A/S	3.00	Buy	$243.36	25.27% Upside
INSM Insmed	2.94	Moderate Buy	$132.57	-2.59% Downside
ONC BeOne Medicines	3.00	Buy	$330.89	8.12% Upside

Current Analyst Ratings Breakdown

Latest ASND, ARGX, ONC, and INSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	ARGX argenex	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$818.00
8/26/2025	ARGX argenex	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$750.00 ➝ $820.00
8/25/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$800.00
8/25/2025	ARGX argenex	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$850.00
8/21/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$126.00 ➝ $144.00
8/20/2025	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$111.00 ➝ $135.00
8/20/2025	INSM Insmed	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
8/19/2025	ASND Ascendis Pharma A/S	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$254.00 ➝ $260.00
8/14/2025	INSM Insmed	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$126.00 ➝ $139.00
8/14/2025	INSM Insmed	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$121.00 ➝ $145.00
8/13/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$114.00 ➝ $142.00

(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$2.25B	19.35	$2.97 per share	239.76	$90.49 per share	7.87
ASND Ascendis Pharma A/S	$393.54M	30.22	N/A	N/A	($1.88) per share	-103.34
INSM Insmed	$363.71M	79.10	N/A	N/A	$1.60 per share	85.06
ONC BeOne Medicines	$4.56B	7.35	N/A	N/A	$34.10 per share	8.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$833.04M	$19.50	36.52	65.64	0.81	40.98%	21.06%	18.25%	10/30/2025 (Estimated)
ASND Ascendis Pharma A/S	-$409.12M	-$5.16	N/A	809.46	N/A	-54.94%	N/A	-24.31%	11/13/2025 (Estimated)
INSM Insmed	-$913.77M	-$5.71	N/A	N/A	N/A	-259.82%	-195.37%	-49.49%	10/30/2025 (Estimated)
ONC BeOne Medicines	-$644.79M	-$1.73	N/A	431.06	N/A	-3.89%	-1.22%	-0.72%	N/A

Latest ASND, ARGX, ONC, and INSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ASND Ascendis Pharma A/S	-$1.42	-$0.93	+$0.49	-$0.93	$163.17 million	$216.28 million
8/7/2025	Q2 2025	INSM Insmed	-$1.30	-$1.70	-$0.40	-$1.70	$104.06 million	$107.42 million
8/6/2025	Q2 2025	ONC BeOne Medicines	$0.48	$0.84	+$0.36	$0.84	$1.24 billion	$1.32 billion
7/31/2025	Q2 2025	ARGX argenex	$2.84	$3.74	+$0.90	$3.74	$776.82 million	$866.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.60	5.27
ASND Ascendis Pharma A/S	N/A	1.02	0.69
INSM Insmed	0.45	6.68	6.33
ONC BeOne Medicines	0.04	1.95	1.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
ASND Ascendis Pharma A/S	N/A
INSM Insmed	N/A
ONC BeOne Medicines	48.55%

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
ASND Ascendis Pharma A/S	40.00%
INSM Insmed	3.00%
ONC BeOne Medicines	6.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,599	61.20 million	59.71 million	Optionable
ASND Ascendis Pharma A/S	1,017	61.21 million	36.73 million	Optionable
INSM Insmed	1,271	211.38 million	205.03 million	Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A

ASND, ARGX, ONC, and INSM Headlines

Recent News About These Companies

BeOne Medicines (NASDAQ:ONC) Shares Gap Up - Here's Why

August 31 at 11:44 AM | marketbeat.com

BeOne Medicines announces positive topline results from phase 1/2 study of sonrotoclax in R/R mantle cell lymphoma

August 30 at 3:41 PM | pharmabiz.comP

Analysts Set BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Price Target at $330.89

August 30 at 2:01 AM | americanbankingnews.com

BeOne Medicines stock rises after positive Phase 1/2 results

August 30 at 2:43 AM | in.investing.com

BeOne Medicines stock rises after positive Phase 1/2 results

August 30 at 2:43 AM | za.investing.com

BeOne Medicines succeeds in Phase 1/2 study for lymphoma therapy

August 30 at 2:43 AM | msn.com

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

August 29 at 6:00 AM | businesswire.com $https://www.businesswire.com/news/home/20250829435188/en/beone-medicines-announces-positive-topline-results-for-sonrotoclax-in-relapsed-or-refractory-mantle-cell-lymphoma-mcl/$

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Receives Average Recommendation of "Buy" from Analysts

August 29 at 3:32 AM | marketbeat.com

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Receives Average Rating of "Buy" from Analysts

August 29 at 3:32 AM | marketbeat.com

BeOne Medicines announces EC approved Tevimbra to treat NSCLC

August 28, 2025 | msn.com

With 42% institutional ownership, BeOne Medicines Ltd. (NASDAQ:ONC) is a favorite amongst the big guns

August 28, 2025 | finance.yahoo.com

BeOne Medicines shares dip after EU greenlights TEVIMBRA for lung cancer

August 27, 2025 | msn.com

BeOne Meds sells Imdelltra royalty for up to $950 million

August 26, 2025 | thepharmaletter.comT

EC approves tablet formulation of BeOne Medicines’ Brukinsa

August 26, 2025 | thepharmaletter.comT

BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

August 26, 2025 | businesswire.com

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

August 25, 2025 | finance.yahoo.com

BeOne Medicines Announces $950 Million Royalty Purchase Agreement with Royalty Pharma for Imdelltra

August 25, 2025 | pharmexec.comP

Royalty Pharma confirms acquisition of royalty interest in Amgen’s Imdelltra

August 25, 2025 | msn.com

BeOne bags $885M upfront in Royalty deal on Amgen's lung cancer drug Imdelltra

August 25, 2025 | fiercepharma.comF

BeOne Medicines to sell royalty rights of Imdelltra to Royalty Pharma for $950M

August 25, 2025 | msn.com

BeOne Medicines’ new film-coated tablet formulation of Brukinsa gets European nod for all approved indications

August 23, 2025 | pharmabiz.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ASND, ARGX, ONC, and INSM Company Descriptions

argenex NASDAQ:ARGX

$712.20 +8.13 (+1.15%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$712.52 +0.31 (+0.04%)

As of 08/29/2025 04:38 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Ascendis Pharma A/S NASDAQ:ASND

$194.27 +0.37 (+0.19%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$194.23 -0.04 (-0.02%)

As of 08/29/2025 04:38 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Insmed NASDAQ:INSM

$136.10 +1.13 (+0.84%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$137.24 +1.14 (+0.84%)

As of 08/29/2025 07:52 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

BeOne Medicines NASDAQ:ONC

$306.05 +8.09 (+2.72%)

As of 08/29/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time